Scarica l'app Stockscreener
1.25
7.41%
-0.10
Pre-mercato:
1.28
0.03
+2.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cardiff Oncology Inc Borsa (CRDF) Ultime notizie
Price to earnings forward of Cardiff Oncology, Inc. – TRADEGATE:XE7C - TradingView
Price to book forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
CRDFCardiff Oncology Inc Dividends - Finviz
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Dynamic Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell Small Cap Completeness Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2500 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Index - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cardiff Oncology, Inc.(NasdaqCM: CRDF) dropped from Russell 3000E Value Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director TANNENBAUM RENEE P - Moomoo
Cardiff Oncology | 4: Statement of changes in beneficial ownership of securities-Director PACE GARY W - Moomoo
Cardiff Oncology, Inc. Actuals & Estimates (NASDAQ:CRDF) - TradingView
Cardiff Oncology, Inc. Actuals & Estimates (FWB:XE7C) - TradingView
Cardiff Oncology Inc (CRDF) Institutional Confidence - TradingKey
Cardiff Oncology, Inc. Actuals & Estimates (LS:A2P4GU) - TradingView
CRDF Forecast — Price Target — Prediction for 2027 - TradingView
Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRDF News | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - ChartMill
Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Daily Brief Health Care: Abbvie Inc, Blueprint Medicines, Cardiff Oncology, Fusion Antibodies , Guangdong True Health Medical Technology Development, High Tide , Nasos Pharma, Teladoc Health, Inc. and more - Smartkarma
Cardiff Oncology director Gary Pace buys $36,600 in stock By Investing.com - Investing.com Australia
CRDF: Phase II Update; Survival Advantage Extended - scr.zacks.com
Cardiff Oncology director Gary Pace buys $36,600 in stock - Investing.com UK
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock By Investing.com - Investing.com Nigeria
Cardiff Oncology CEO Mani Mohindru buys $29,890 in company stock - Investing.com
Form 4 Cardiff Oncology Inc For: 22 June By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
Cardiff Oncology (CRDF) Stifel 2025 Healthcare Conference Summary - Quartr
Cardiff Oncology (CRDF) Proxy filing Summary - Quartr
Cardiff Oncology Inc (CRDF) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiff Oncology Inc (CRDF) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cardiff Oncology Inc (CRDF) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cardiff Oncology (CRDF) director receives 40,565 stock options at $1.59 strike - Stock Titan
Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59 - Stock Titan
Cardiff Oncology Shareholders Approve Directors and Equity Plan - TipRanks
Cardiff Oncology (CRDF) shareholders back board, auditor and equity plan - Stock Titan
Cardiff Oncology (CRDF) Holds Steady at $1.50 as Key Levels Define Trading RangeProtective Put - newsline.com
Cardiff Oncology (CRDF) Slips 1% as Stock Hovers Near Key Support LevelFibonacci Extension - dars.gov.et
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal CancerSlideshow (NASDAQ:CRDF) 2026-06-07 - Seeking Alpha
CRDF Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline ProgressesQuarterly Earnings Report - dars.gov.et
3.27%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):